Epstein Secrets

this for your attention. Our view is that there is good risk-reward for TEVA going into a patent decision expected tomorrow relating to its key drug Copaxone Copaxone US is - 16% of sales, ^21% globally)). If the decision is unfavorable, we would likely look to add on any weakness. Our analyst is already building in

laims are granted, TEVA will be viewed as the winner (given burden of proof is on the generics). Also note that the traditional P-IV challenge from MNTA/Sandoz/MYL/Amneal/Synthon/PFE/DRRD will kick off 26-Sep. 4 Net/net, a victory for TEVA likely sees a 10%+ move higher in my view (S58ish) while a negative out

this for your attention. Our view is that there is good risk-reward for TEVA going into a patent decision expected tomorrow relating to its key drug Copaxone Copaxone US is —16% of sales, —21% globally)). If the decision is unfavorable, we would likely look to add on any weakness. Our analyst is already building in c

laims are granted, TEVA will be viewed as the winner (given burden of proof is on the generics). Also note that the traditional P-IV challenge from MNTA/Sandoz/MYL/AmneaUSynthon/PFE/DRRD will kick off 26-Sep. 4 Net/net, a victory for TEVA likely sees a 10%+ move higher in my view (S58ish) while a negative outc

this for your attention. Our view is that there is good risk-reward for TEVA going into a patent decision expected tomorrow relating to its key drug Copaxone Copaxone US is —16% of sales, —21% globally)). If the decision is unfavorable, we would likely look to add on any weakness. Our analyst is already building in

laims are granted, TEVA will be viewed as the winner (given burden of proof is on the generics). Also note that the traditional P-IV challenge from MNTA/Sandoz/MYL/Amneal/Synthon/PFE/DRRD will kick off 26-Sep. 4 Net/net, a victory for TEVA likely sees a 10%+ move higher in my view (S58ish) while a negative ou